Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$58.93 - $95.25
Next Earnings Date
Jul 22 2025 (Estimate)
Next Earnings Date
Jul 22 2025 (Est.)
Latest price
Market Cap | $41.27B |
EV | $38.06B |
Shares Outstanding | 585.76M |
Beta | 1.15 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $80.08 |
P/E 2025E | 28.61x |
P/Revenue 2025E | 7.03x |
Revenue | 1.30% |
EPS | 3.10% |
Operating Cash Flow | -32.10% |
Free Cash Flow | -40.90% |
Revenue | 9.50% |
EPS | 8.50% |
Operating Cash Flow | 53.20% |
Free Cash Flow | 81.90% |
Gross Margin 2025E | 78.42% |
Net Profit Margin 2025E | 23.93% |
ROE 2025E | 13.28% |
ROCE 2024 | 16.83% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Edwards Lifesciences Corporation
EW
Sector
Healthcare
Industry
Medical - Devices
CEO
Zovighian, Bernard
Employees
15,800
Website
www.edwards.comIPO Date
2000-03-27
Headquarters
One Edwards Way, Irvine, California, 92614, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved